Latest news with #HealthCareSPDRETF
Yahoo
14-07-2025
- Business
- Yahoo
Why Owens & Minor (OMI) Shares Are Trading Lower Today
Shares of medical supply and logistics company Owens & Minor (NYSE:OMI) fell 3.2% in the morning session after continued pressure from the previous week's announcement of potential new U.S. tariffs on Canada. The negative sentiment follows news from late last week that the U.S. administration was considering a significant 35% tariff on Canadian imports, sparking fears of a broader trade dispute. The healthcare sector is seen as particularly vulnerable to such tensions because of its deeply integrated supply chains with Canada for various medical devices and products. For a medical supply and logistics company like Owens & Minor, the prospect of new tariffs raises concerns about increased operational costs and potential disruptions. This uncertainty is weighing on investor sentiment, as a trade war could pressure profit margins for companies reliant on cross-border trade for their supplies and distribution networks. The stock's move reflects broader market anxiety about the economic impact of protectionist trade policies. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Owens & Minor? Access our full analysis report here, it's free. Owens & Minor's shares are extremely volatile and have had 44 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 3% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. Owens & Minor is down 38.8% since the beginning of the year, and at $7.86 per share, it is trading 52.3% below its 52-week high of $16.48 from July 2024. Investors who bought $1,000 worth of Owens & Minor's shares 5 years ago would now be looking at an investment worth $1,026. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
11-07-2025
- Business
- Yahoo
Masimo, STAAR Surgical, Teleflex, Omnicell, and Integra LifeSciences Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Patient Monitoring company Masimo (NASDAQ:MASI) fell 3.1%. Is now the time to buy Masimo? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company STAAR Surgical (NASDAQ:STAA) fell 3.4%. Is now the time to buy STAAR Surgical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) fell 3%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) fell 3.7%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) fell 4.6%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Integra LifeSciences's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Integra LifeSciences is down 45.1% since the beginning of the year, and at $12.63 per share, it is trading 60.2% below its 52-week high of $31.74 from July 2024. Investors who bought $1,000 worth of Integra LifeSciences's shares 5 years ago would now be looking at an investment worth $272.55. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Hospital Chains company Acadia Healthcare (NASDAQ:ACHC) fell 3.1%. Is now the time to buy Acadia Healthcare? Access our full analysis report here, it's free. Genomics & Sequencing company 10x Genomics (NASDAQ:TXG) fell 3.1%. Is now the time to buy 10x Genomics? Access our full analysis report here, it's free. Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) fell 3%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it's free. Therapeutics company Myriad Genetics (NASDAQ:MYGN) fell 3.1%. Is now the time to buy Myriad Genetics? Access our full analysis report here, it's free. Medical Devices & Supplies - Imaging, Diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 3.8%. Is now the time to buy QuidelOrtho? Access our full analysis report here, it's free. QuidelOrtho's shares are very volatile and have had 27 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. QuidelOrtho is down 32.3% since the beginning of the year, and at $30.48 per share, it is trading 36% below its 52-week high of $47.61 from January 2025. Investors who bought $1,000 worth of QuidelOrtho's shares 5 years ago would now be looking at an investment worth $129.97. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
